ESMO and the European Haematology Association (EHA) – the professional organisation representing haematologists in Europe – have recently agreed to collaborate on the production of European guidelines for haematological malignancies.
Through this collaboration, which aims at further promoting the existing knowledge in patient care, new research, and education in haemato-oncology, ESMO and EHA will commit to jointly produce and spread guidelines on blood tumours.
Further to a review by the corresponding EHA Scientific Working Groups in a standardised review process, EHA has already endorsed the most recent ESMO Guidelines on blood disorders, namely Marginal zone lymphomas and Mantle cell lymphoma.
To further disseminate the guidelines, a series of workshops have been organised by EHA. The first one is scheduled on 15 December at 16:00 CET and will focus on the ESMO Clinical Practice Guidelines on Hodgkin Lymphoma, published online in Annals of Oncology in November 2020: two of the lead authors will present the guideline and illustrate their application in current clinical scenarios.
Through the ESMO-EHA collaboration the following COVID-19-adapted recommendations have also been published:
- ESMO-EHA Clinical Practice Guidelines for the management of malignant lymphoma - Recommendations for the second phase of the COVID-19 pandemic: Aggressive lymphoma (diffuse large B-cell lymphoma, Mantle cell and T-cell lymphomas)
- ESMO-EHA Clinical Practice Guidelines for the management of malignant lymphoma - Recommendations for the second phase of the COVID-19 pandemic: Hodgkin lymphoma
- ESMO-EHA Clinical Practice Guidelines for the management of malignant lymphoma - Recommendations for the second phase of the COVID-19 pandemic: Indolent B-NHL (Follicular and Marginal Zone Lymphoma, Waldenström’s Macroglobulinaemia)
The first fully joint ESMO-EHA guideline will be published in the new year in Annals of Oncology and HemaSphere and will be on multiple myeloma.